Skip to main content

Table 1 Subject characteristics

From: New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

 

(A) Standard treatment interval

(B) Extended treatment intervals

(C) Cessation

NAT

Non-NAT

4 weeks

5 weeks

8 weeks

 

Number of patients

27

24

18

18

10

18

Women (%)

60

70

50

72

67

61

Age in years (mean ± SD)

35.4 ± 9.4

38.5 ± 12.1

36.9 ± 9.4

44.8 ± 6.7

42.7 ± 8.5

38.3 ± 10.2

Years of disease (mean ± SD)

8.9 ± 6.8

1.4 ± 4.6

8.9 ± 6.8

14.5 ± 7.5

10.0 ± 3.0

10.4 ± 8.3

EDSSa (mean ± SD)

3.5 ± 1.6

2.5 ± 1.6

3.5 ± 1.6

3.7 ± 1.1

3.3 ± 1.53

3.7 ± 1.9

  1. aEDSS, Kurtzke Expanded Disability Status Scale